Randomized, controlled, double-blind multicenter comparison, of the efficacy and tolerability of ziprasidone and olanzapine in acutely III inpatients with schizophrenia or schizoaffective disorder

American Journal of Psychiatry

Volumn 161, Issue 10, 2004, Pages 1837-1847

  Simpson, George M ^a   Glick, Ira D ^b   Weiden, Peter J ^b   Romano, Steven J ^b   Siu, Cynthia O ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; GLUCOSE; INSULIN; LIPID; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ACUTE DISEASE; ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSTONIA; ELECTROCARDIOGRAPHY; FEMALE; HEALTH STATUS; HOSPITAL PATIENT; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONITORING; MOTOR DYSFUNCTION; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4744338410     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.161.10.1837     Document Type: Article

References (58)

1. Stip E: Novel antipsychotics: issues and controversies: typicality of atypical antipsychotics. J Psychiatry Neurosci 2000; 52:137-153
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
3. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (Ziprasidone Study Group): Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20:491-505
4. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140:173-184
5. Keck PE, Reeves KR, Harrigan EP (Ziprasidone Study Group): Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled multicenter trials. J Clin Psychopharmacol 2001; 21:27-35
6. Arato M, O'Connor R, Meltzer HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17:207-215
7. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304
8. Hirsch S, Kissling W, Bäuml J, Power A, O'Connor R: A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63:516-523
9. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201
10. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62:347-349
11. Briefing Document for Zeldox Capsules (Ziprasidone HCl). New York, Pfizer Inc, FDA Psychopharmacological Drugs Advisory Committee, July 19, 2000
12. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159-167
13. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
14. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
15. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407-418
16. Beaseley CM Jr, Hamilton SH, Crawford AM, Tollefson G, Tran P, Blin O, Beuzen J-N: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Neuropsychopharmacology 1997; 7:125-137
17. Gomez JC, Crawford AM: Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry 2001; 62(suppl 2):6-11
18. Madhusoodanan S, Brenner R, Suresh P, Concepcion NM, Florita CD, Menon G, Kaur A, Nunez G, Reddy H: Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12:11-18
19. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205-211
20. Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765-774; correction, 158:1759
21. Baptista T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100:3-16
22. Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical antipsychotics, part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33:210-217
23. Collaborative Working Group on Clinical Trial Evaluations: Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59(suppl 12):17-22
24. Ganguli R: Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60(suppl 21):21-24
25. Sachs GS, Guille C: Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(suppl):16-19
26. Wetterling T, Mussigbrodt HE: Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19:316-321
27. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G: Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22:224-235
28. Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770
29. Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21:369-374
30. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML: Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34:865-867
31. Bonanno DG, Davydov L, Botts SR: Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35:563-565
32. Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25-32
33. Muench J, Carey M: Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14:278-282
34. Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16:63-73
35. Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77-89
36. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566
37. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
38. Chouinard G, Ross-Chouinard A, Annable L, Jones B: Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233
39. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
40. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
42. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22:818-822
43. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23:57-63
44. Blackwelder WC: "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982; 3:345-353
45. Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART), 5th Ed. Rockville, Md, US Food and Drug Administration, Center for Drug Evaluation and Research, 1995
46. Pi-Sunyer FX: The obesity epidemic: pathophysiology and consequences of obesity. Obesity Res 2002; 10(suppl 2):97S-104S
47. Manson JE, Stampfer MJ, Hennekens CH, Willett WC: Body weight and longevity: a reassessment. JAMA 1987; 257:353-358
48. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497
49. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D (Multiple Risk Factor Intervention Trial Research Group): Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152:1490-1500
50. Miller M: The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol 1999; 22(suppl 2):1-6
51. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219
52. Laaskso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137:959-965
53. Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103:152-162
54. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100
55. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A: The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187:496-502
56. Brown S, Inskip H, Barraclough B: Causes of excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217
57. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP: Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22:413-430
58. Romano SJ: Cardiovascular safety profile of ziprasidone: review of clinical development data, in 2001 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 2001, number 251